Bristol Myers Net Worth
Bristol Myers Net Worth Breakdown | BMY |
Bristol Myers Net Worth Analysis
Bristol Myers' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Bristol Myers' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Bristol Myers' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Bristol Myers' net worth analysis. One common approach is to calculate Bristol Myers' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Bristol Myers' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Bristol Myers' net worth. This approach calculates the present value of Bristol Myers' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Bristol Myers' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Bristol Myers' net worth. This involves comparing Bristol Myers' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Bristol Myers' net worth relative to its peers.
Enterprise Value |
|
To determine if Bristol Myers is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bristol Myers' net worth research are outlined below:
| Bristol Myers Squibb has a strong financial position based on the latest SEC filings | |
| Over 79.0% of the company shares are held by institutions such as insurance companies | |
| On 1st of November 2024 Bristol Myers paid $ 0.6 per share dividend to its current shareholders | |
| Latest headline from bbc.co.uk: Wrexham Matt Taylors Bristol Rovers departure creates unpredictability - Phil Parkinson |
Bristol Myers Quarterly Good Will |
|
Bristol Myers uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bristol Myers Squibb. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bristol Myers' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 2nd of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 2nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Bristol Myers' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bristol Myers is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bristol Myers Squibb backward and forwards among themselves. Bristol Myers' institutional investor refers to the entity that pools money to purchase Bristol Myers' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of New York Mellon Corp | 2024-09-30 | 23.3 M | Northern Trust Corp | 2024-09-30 | 21.2 M | T. Rowe Price Associates, Inc. | 2024-09-30 | 20.2 M | Ameriprise Financial Inc | 2024-09-30 | 20.1 M | Legal & General Group Plc | 2024-09-30 | 20 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 19.1 M | Bank Of America Corp | 2024-09-30 | 18.1 M | Amvescap Plc. | 2024-09-30 | 16.2 M | Dodge & Cox | 2024-09-30 | 15.6 M | Vanguard Group Inc | 2024-09-30 | 188.6 M | Blackrock Inc | 2024-06-30 | 158.7 M |
Follow Bristol Myers' market capitalization trends
The company currently falls under 'Mega-Cap' category with a total capitalization of 116.78 B.Market Cap |
|
Project Bristol Myers' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.17 | 0.15 | |
| Return On Capital Employed | 0.24 | 0.29 | |
| Return On Assets | 0.08 | 0.14 | |
| Return On Equity | 0.27 | 0.30 |
When accessing Bristol Myers' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Bristol Myers' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bristol Myers' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Bristol Myers' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bristol Myers Squibb. Check Bristol Myers' Beneish M Score to see the likelihood of Bristol Myers' management manipulating its earnings.
Evaluate Bristol Myers' management efficiency
Bristol Myers Squibb has Return on Asset of 0.0607 % which means that on every $100 spent on assets, it made $0.0607 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3133) %, meaning that it generated no profit with money invested by stockholders. Bristol Myers' management efficiency ratios could be used to measure how well Bristol Myers manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Bristol Myers' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.14 in 2024, whereas Return On Tangible Assets are likely to drop 0.15 in 2024. At this time, Bristol Myers' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 66.6 B in 2024, whereas Other Assets are likely to drop slightly above 3.3 B in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 14.25 | 14.96 | |
| Tangible Book Value Per Share | (9.07) | (8.61) | |
| Enterprise Value Over EBITDA | 7.03 | 12.19 | |
| Price Book Value Ratio | 3.61 | 6.92 | |
| Enterprise Value Multiple | 7.03 | 12.19 | |
| Price Fair Value | 3.61 | 6.92 | |
| Enterprise Value | 107.1 B | 112.4 B |
Bristol Myers Squibb has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 3.3642 | Revenue 47.4 B | Quarterly Revenue Growth 0.084 | Revenue Per Share 23.41 | Return On Equity (0.31) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bristol Myers insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bristol Myers' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bristol Myers insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Peter Arduini over three months ago Acquisition by Peter Arduini of 825 shares of Bristol Myers subject to Rule 16b-3 | ||
Hoch Lynelle over six months ago Disposition of 1050 shares by Hoch Lynelle of Bristol Myers subject to Rule 16b-3 | ||
Phyllis Yale over a year ago Acquisition by Phyllis Yale of 581 shares of Bristol Myers subject to Rule 16b-3 |
Bristol Myers Corporate Filings
ASR | 13th of December 2024 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
13A | 13th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Bristol Myers Earnings per Share Projection vs Actual
Bristol Myers Corporate Directors
| Karen Vousden | Independent Director | Profile | |
| Michael Bonney | Independent Director | Profile | |
| Robert Bertolini | Independent Director | Profile | |
| Gerald Storch | Independent Director | Profile |
Additional Tools for Bristol Stock Analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.